biologic

TNKase

tenecteplase

Loss of exclusivityFebruary 2037projected — 12-year biologic exclusivity estimate
CompanyGenentechView the full company profile on CliffBio

Drug detail

Brand nameTNKase
Active ingredienttenecteplase
Strength25MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2025
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found